Sanofi confirms your interest in Argentina. The French laboratory, specializing in vaccination, announced an investment of US $ 2 million by 2025 In its plant located in the province of Buenos Aires, one of the 50 that has globally.
The disbursement is part of a current investment plan, which the company allocates every year to update processes and technologies on the site. Since 2005, when it was inaugurated, the firm invested more than US $ 70 million.
“As of 2005, with knowledge and work team, industrialization began and the decision to assemble the plant here, and continue. The plant has an excellent performance and continues to expand,” said Rocío Bassans, CEO of Sanofi Vaccines in Argentina.
Located in Pilar’s party, the plant is the only one in the world that manufactures the hepatitis B antigen, One of the nine antigens that make up the hexavalent acellular pediatric vaccine. It is a vaccine that protects against six diseases: hepatitis B, diphtheria, tetanus, pertussis or convulsive cough, polyomyelitis, and Haemophilus influenzae Type B.
The antigen is exported to France, where the firm ends the process and distributes the final product in more than 100 countries. According to the data exhibited by the company, since its launch globally in 2013, more than 210 million doses were distributed: in Argentina, it is marketed under the Hexaxim brand and is part of the national vaccination calendar.
The plant, which uses around 150 collaborators, It has a production capacity of 100 million doses per year of the antigen of hepatitis B, which represents US $ 37 million in export. As they specified, the manufacturing process extends for 18 days – from fermentation until the final filtration – to which another period of 17 and 23 days of maturation is added.
There, since 2021, Sanofi has been the production project of the Meningitis B antigen. And performs the repapatory and quality control process of 15 vaccines for local marketing.
Facing 2028, the firm outlined a program, consisting of three stages. “The first pillar is to maximize what we have. Today, our great battle knight is the influenza vaccine. The second pillar is to expand and win new markets with competitive products. And the third is to consolidate as pioneers in new areas of diseases with unsatisfied needs, such as acne and chlamydia,” said Florencia Esquivel, medical director of Vaccines for Latin America in SANOFI.
